Discovery of a novel class of BK channel openers: Enantiospecific synthesis and BK channel opening activity of 3-(5-chloro-2-hydroxyphenyl)-1,3-dihydro-3- hydroxy-6-(trifluoromethyl)-2H-indol-2-one

Bioorganic and Medicinal Chemistry Letters

Volumn 7, Issue 10, 1997, Pages 1255-1260

  Hewawasam, Piyasena ^a   Meanwell, Nicholas A ^a   Gribkoff, Valentin K ^a   Dworetzky, Steven I ^a   Boissard, Christopher G ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 CHLORO 2 HYDROXYPHENYL) 5 TRIFLUOROMETHYL 2 BENZIMIDAZOLONE; INDOLE DERIVATIVE; POTASSIUM CHANNEL; POTASSIUM CHANNEL STIMULATING AGENT;

ANIMAL CELL; ARTICLE; CHANNEL GATING; CHIRALITY; CONTROLLED STUDY; DRUG SYNTHESIS; ELECTROPHYSIOLOGY; GENE EXPRESSION; HUMAN; MOLECULAR CLONING; NONHUMAN; OOCYTE; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; XENOPUS LAEVIS;

ANIMALIA; XENOPUS LAEVIS;

EID: 0031579961     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(97)00202-3     Document Type: Article

References (27)

1. Department of Chemistry.
2. Department of Central Nervous System Drug Discovery.
3. Cook N.S. Trends in Pharmacol. Sciences. 9:1988;21.
4. Quast U., Cook N.S. Trends in Pharmacol. Sciences. 10:1989;431.
5. Longman S.D., Hamilton T.C. Med. Res. Rev. 12:1992;73.
6. Atwal K. Med. Res. Rev. 12:1992;569.
7. Gopalakrishnan M., Janis R., Triggle D. Drug Dev. Res. 28:1993;95.
8. Latorre R., Oberhauser A., Labarca P., Alvarez O. Ann. Rev. Physiol. 51:1989;385.
9. Sah P. Trends Neurosci. 19:1996;150.
10. Starrett J.E., Dworetzky S.I., Gribkoff V.K. Curr. Pharm. Des. 2:1996;413.
11. Gribkoff V.K., Starrett J.E., Dworetzky S.I. Adv. Pharmacology. 37:1996;319.
12. Olesen S.-P. Exp. Opin. Invest. Drugs. 3:1994;1181.
13. Olesen S.-P., Munch E., Moldt P., Drejer J. Eur. J. Pharmacol. 251:1994;53.
14. Olesen S.-P., Munch E., Wätjen F., Drejer J. Neuro Report. 5:1994;1001.
15. McKay M.C., Dworetzky S.I., Meanwell N.A., Olesen S.-P., Reinhart P.H., Levitan I.B., Adelman J.P., Gribkoff V.K. J. Neurophysiol. 71:1994;1873.
16. Xu X., Tsai T.D., Wang J., Lee E.W., Lee K.S. J. Pharm. Exp. Ther. 271:1994;362.
17. Edwards G., Niederste-Hollenberg A., Schneider J., Noack Th., Weston A.H. Br. J. Pharmacol. 113:1994;1538.
18. Lee K., Rowe I.C.M., Ashford M.L.J. Eur. J. Pharmacol. 280:1995;215.
19. Meanwell N.A., Sit S.-Y., Gao J., Boissard C.G., Lum-Ragan J., Dworetzky S.I., Gribkoff V.K. Bioorg. Med. Chem. Lett. 6:1996;1641.
20. Hewawasam P., Meanwell N.A. Tetrahedron Lett. 35:1994;7303.
21. Davis F.A., Chen B-C. Chem. Rev. 92:1992;919.
22. It was found that the enolate of 6 is quite sensitive to even trace amounts of dissolved oxygen and readily undergoes autooxidation, which results in signicficantly reduced asymmetric induction. In order to prevent hydroxylation by molecular oxygen, asymmetric hydroxylation of indolone 6 with the oxaziridines 7 was performed in degassed dry THF under an argon atmosphere.
23. Previously, chiral shift reagents have been used to determine the enantiomeric excess of chiral alcohols as described in . However, for this series of chiral alcohols, we have found that the use of the chiral solvent (L)-trifluoromethylphenyl carbinol can be used in place of chiral shift reagents to effectively determine the enantiomeric excess of 4c and 4e.
24. In order to establish the absolute stereochemistry of the asymmetric hydroxylation protocol, the absolute configuration of a chiral 5-bromo-3-hydroxyindolone analogue was determined by single crystal X-ray analysis. Thus, oxidation of the potassium enolate of 5-bromo-3-(5-chloro-2-methoxyphenyl)-1,3-dihydro-2H-indol-2-one with (1S)-(+)-(10-camphorsulfonyl)oxaziridine afforded (3R)-(-)-5-bromo-3-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-hydroxy-2H-indol-2-one.
25. Butler A., Tsunoda S., McCobb D.P., Wei A., Salkoff L. Science. 261:1993;221.
26. Dworetzky S.I., Trojnacki J.T., Gribkoff V.K. Mol. Brain Res. 27:1994;189.
27. Gribkoff V.K., Lum-Ragan J.T., Boissard C.G., Post-Munson D.J., Meanwell N.A., Starrett J.E. Jr., Kozlowski E.S., Romine J.L., Trojnacki J.T., McKay M.C., Zhong J., Dworetzky S.I. Mol. Pharmacol. 50:1996;206.